These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32435754)

  • 1. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.
    McSweeney L; Breckons M; Fattakhova G; Oluboyede Y; Vale L; Ternent L; Balp MM; Doward L; Brass CA; Beyer F; Sanyal A; Anstee QM
    JHEP Rep; 2020 Jun; 2(3):100099. PubMed ID: 32435754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
    Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
    JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
    O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
    JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review.
    Kennedy-Martin T; Bae JP; Paczkowski R; Freeman E
    J Patient Rep Outcomes; 2017; 2():28. PubMed ID: 29984351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.
    Yamamura S; Nakano D; Hashida R; Tsutsumi T; Kawaguchi T; Okada M; Isoda H; Takahashi H; Matsuse H; Eguchi Y; Sumida Y; Nakajima A; Gerber L; Younossi ZM; Torimura T
    J Gastroenterol Hepatol; 2021 Mar; 36(3):629-636. PubMed ID: 32627871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review.
    Grønkjær LL; Lauridsen MM
    JHEP Rep; 2021 Dec; 3(6):100370. PubMed ID: 34805816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
    Younossi ZM; Stepanova M; Younossi I; Racila A
    Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2093-2100.e3. PubMed ID: 30639779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry.
    Younossi ZM; Yilmaz Y; Yu ML; Wai-Sun Wong V; Fernandez MC; Isakov VA; Duseja AK; Mendez-Sanchez N; Eguchi Y; Bugianesi E; Burra P; George J; Fan JG; Papatheodoridis GV; Chan WK; Alswat K; Saeed HS; Singal AK; Romero-Gomez M; Gordon SC; Roberts SK; El Kassas M; Kugelmas M; Ong JP; Alqahtani S; Ziayee M; Lam B; Younossi I; Racila A; Henry L; Stepanova M;
    Clin Gastroenterol Hepatol; 2022 Oct; 20(10):2296-2306.e6. PubMed ID: 34768009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
    Younossi ZM; Stepanova M; Lawitz EJ; Reddy KR; Wai-Sun Wong V; Mangia A; Muir AJ; Jacobson I; Djedjos CS; Gaggar A; Myers RP; Younossi I; Nader F; Racila A
    Am J Gastroenterol; 2019 Oct; 114(10):1636-1641. PubMed ID: 31464743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-walk of the Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) and the EuroQol EQ-5D-5L in patients with NASH.
    Fishman J; Higgins V; Piercy J; Pike J
    Health Qual Life Outcomes; 2023 Oct; 21(1):113. PubMed ID: 37838660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease.
    Zachou K; Azariadis K; Lytvyak E; Snijders RJALM; Takahashi A; Gatselis NK; Robles M; Andrade RJ; Schramm C; Lohse AW; Tanaka A; Drenth JPH; Montano-Loza AJ; Dalekos GN;
    JHEP Rep; 2023 Aug; 5(8):100778. PubMed ID: 37456672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study.
    Yilmaz Y; Toraman AE; Alp C; Doğan Z; Keklikkiran C; Stepanova M; Younossi Z
    Aliment Pharmacol Ther; 2023 Jan; 57(2):215-223. PubMed ID: 36369643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study.
    Doward LC; Balp MM; Twiss J; Slota C; Cryer D; Brass CA; Anstee QM; Sanyal AJ
    Patient; 2021 Sep; 14(5):533-543. PubMed ID: 33336323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Younossi ZM; Stepanova M; Anstee QM; Lawitz EJ; Wai-Sun Wong V; Romero-Gomez M; Kersey K; Li G; Subramanian GM; Myers RP; Djedjos CS; Okanoue T; Trauner M; Goodman Z; Harrison SA
    Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2552-2560.e10. PubMed ID: 30779990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt.
    Alqahtani SA; Yilmaz Y; El-Kassas M; Alswat K; Sanai F; AlZahrani M; Abaalkhail F; AlShaikh M; Al-Hamoudi WK; Nader F; Stepanova M; Younossi ZM;
    J Viral Hepat; 2024 Jun; 31(6):300-308. PubMed ID: 38622910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review.
    Isa F; Turner GM; Kaur G; Kyte D; Slade A; Pankhurst T; Kerecuk L; Keeley T; Ferguson J; Calvert M
    Health Qual Life Outcomes; 2018 Jul; 16(1):133. PubMed ID: 29976215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The burden of nonalcoholic steatohepatitis (NASH) in the United States.
    Tapper EB; Krieger N; Przybysz R; Way N; Cai J; Zappe D; McKenna SJ; Wall G; Janssens N; Balp MM
    BMC Gastroenterol; 2023 Apr; 23(1):109. PubMed ID: 37020273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH).
    Chawla KS; Talwalkar JA; Keach JC; Malinchoc M; Lindor KD; Jorgensen R
    BMJ Open Gastroenterol; 2016; 3(1):e000069. PubMed ID: 27110379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Small Intestinal Bacterial Overgrowth Syndrome in Patients with Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis: A Cross-Sectional Study.
    Gkolfakis P; Tziatzios G; Leite G; Papanikolaou IS; Xirouchakis E; Panayiotides IG; Karageorgos A; Millan MJ; Mathur R; Weitsman S; Dimitriadis GD; Giamarellos-Bourboulis EJ; Pimentel M; Triantafyllou K
    Microorganisms; 2023 Mar; 11(3):. PubMed ID: 36985296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.